Skip to content

Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients

Proving Utility of a New Field-cycling MRI Prototype in Acute Stroke Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07004140
Acronym
PUFFINS 3
Enrollment
40
Registered
2025-06-04
Start date
2025-09-16
Completion date
2026-05-01
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke Acute

Keywords

Stroke, Field-Cycling Imaging, FCI

Brief summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can show changes in the brain within the first day of a stroke due to a blocked blood vessel or bleeding in the brain. The main question it aims to answer is: • Can FCI identify brain tissue that might recover within the first few hours after a stroke begins? Participants will undergo a standard MRI scan and an FCI scan, as soon as possible after hospital admission. Participants who have had a blocked blood vessel will also provide a blood sample and will have a follow up visit at 30 days for repeat of both scans and providing another blood sample.

Interventions

Baseline MRI scan

Day 30 3T MRI scan

OTHERBlood samples for clotting experiments in vitro

Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.

Sponsors

University of Aberdeen
Lead SponsorOTHER
NHS Grampian
CollaboratorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute stroke (\<24 hours from symptom onset). * NIHSS ≥4 and \<25 with cortical involvement and/or large vessel occlusion on baseline imaging. * Able to undergo 3T and FCI MRI \<24h of onset. * With or without thrombolysis.

Exclusion criteria

* Contraindications to MRI. * Medically unstable. * Unable to comprehend or comply with instructions regarding scanning * Prior mRS of \>3. * Identified for thrombectomy. * Non-stroke pathology or previous cortical infarct on CT scan \> 1/3 of middle cerebral artery territory.

Design outcomes

Primary

MeasureTime frameDescription
Agreement between extent of ischaemic stroke at-risk tissue/infarct core obtained from FCI dispersion maps and 3T MRI modalities at baselineBaseline at stroke onsetReceiver operator curves (ROC) curves comparing extent of at-risk tissue/infarct core obtained from FCI dispersion maps and from 3T MRI modalities at baseline at stroke onset.

Secondary

MeasureTime frameDescription
Agreement between extent of haemorrhagic volume obtained from FCI dispersion maps and 3T MRI modalities at baselineBaseline at stroke onsetReceiver operator curves (ROC) curves comparing extent of haemorrhagic volume obtained from FCI dispersion maps and from 3T MRI modalities at baseline at stroke onset.
Agreement of infarct core volume measurements obtained from FCI and 3T MRI at day 30 in ischaemic stroke patients30 days after stroke onsetComparison of infarct core volumes on 30-day 3T FLAIR and baseline/30-day FCI T1 dispersion maps in ischaemic stroke patients.
Agreement between T1 dispersion curve measurements obtained from in vivo clot in large intracerebral vessels and clot formed in vitro.At baseline and 30 days after stroke onsetExtent of agreement between quantified T1 dispersion curve measurements obtained from in vivo imaging and benchtop Fast Field Cycling Nuclear Magnetic Resonance (FFC-NMR). Extent of correlation between thrombo-elastography measurements against in vivo measurements of T1 dispersion.

Countries

United Kingdom

Contacts

CONTACTMary Joan MacLeod, PhD
m.j.macleod@abdn.ac.uk+44 1224 437842
CONTACTGordon D Waiter, PhD
g.waiter@abdn.ac.uk+44 1224 438356

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026